A comparison of C+SCAV and SEAM conditioning regimens in efficacy and safety in autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma patients

This study aimed to compare the efficacy and safety of cladribine, smustine, etoposide, cyclophosphamide, and cytarabine (C+SCAV) and smustine, etoposide, cytarabine, and melphalan (SEAM) conditioning regimens in autologous stem cell transplantation (auto-HSCT) for non-Hodgkin's lymphoma (NHL)...

Full description

Saved in:
Bibliographic Details
Published inZhōnghuá xuèyèxué zázhì Vol. 43; no. 8; pp. 668 - 673
Main Authors Li, J Q, Zhang, Y, Geng, H Z, Jia, S X, Wu, X J, Zhou, J, Zong, X P, Yang, Z, Chen, X C, Ma, C, Chen, G H, Dai, H P, Li, C X, Wu, D P
Format Journal Article
LanguageChinese
Published China 14.08.2022
Subjects
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cytarabine - therapeutic use
Etoposide - therapeutic use
Female
Hematopoietic Stem Cell Transplantation
Humans
Lymphoma, Non-Hodgkin - drug therapy
Male
Melphalan - therapeutic use
Middle Aged
Retrospective Studies
Transplantation Conditioning - adverse effects
Transplantation, Autologous
Young Adult
Conditioning regimen
Non-Hodgkin lymphoma
Autologous stem cell transplantation
Cladribine
Online AccessGet full text

Cover

More Information
Summary:This study aimed to compare the efficacy and safety of cladribine, smustine, etoposide, cyclophosphamide, and cytarabine (C+SCAV) and smustine, etoposide, cytarabine, and melphalan (SEAM) conditioning regimens in autologous stem cell transplantation (auto-HSCT) for non-Hodgkin's lymphoma (NHL) . A retrospective analysis was conducted on 61 NHL patients who received auto-HSCT in the Department of Hematology, the First Affiliated Hospital of Suzhou University, from March 2018 to May 2021. The C + SCAV group and SEAM group had 19 and 42 patients, respectively. ① Among the 61 patients with NHL, 37 were male and 24 were female. The median age was 48 (21-66) years old. There were 19 cases in the C+SCAV group and 42 cases in the SEAM group. There was no significant difference in the baseline characteristics between the two groups ( >0.05) . ② The median time to neutrophil and platelet engraftment in the C+SCAV cohort were 10 (8-15) days and 13 (9-22) days, respectively, which does not differ from the SEAM group ( =0
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0253-2727
DOI:10.3760/cma.j.issn.0253-2727.2022.08.009